Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „formulation“
Suchtreffer
Begriffe & Kennungen
Herceptin · 4.8 · Some adverse events / reactions were reported with a higher frequency for the subcutaneous formulation: Seri
Eintrag öffnenHerceptin · 4.8 · Study MO22982 investigated switching between the Herceptin intravenous and Herceptin subcutaneous formulation
Eintrag öffnenHerceptin · 4.8 · Study MO22982 investigated switching between the Herceptin intravenous and Herceptin subcutaneous formulation
Eintrag öffnenHerceptin · 4.8 · Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulation and vice versa
Eintrag öffnenHerceptin · 4.8 · Switching treatment between Herceptin intravenous and Herceptin subcutaneous formulation and vice versa
Eintrag öffnenHerceptin · 4.8 · Tabulated list of adverse reactions with the intravenous formulation
Eintrag öffnenHyQvia · 4.8 · The most frequent adverse reactions reported during post-marketing use of rHuPH20 in similar formulations admi
Eintrag öffnenINOmax · 4.5 · 18 REG-15307/v.43 Page 18/56 oral, parenteral, or topical formulations may cause methaemoglobinaemia. Care mus
Eintrag öffnenInvega · 4.8 · Undesirable effects noted with risperidone formulations Paliperidone is the active metabolite of risperidone,
Eintrag öffnenIsentress · 4.8 · ISENTRESS 600 mg tablet formulation has not been studied in paediatric patients (see section 4.2).
Eintrag öffnenIvemend · 4.8 · Summary of the safety profile In clinical studies, various formulations of fosaprepitant have been administere
Eintrag öffnenKeytruda · 4.8 · Intravenous formulation The safety of pembrolizumab as monotherapy has been evaluated in 161 paediatric patien
Eintrag öffnenKeytruda · 4.8 · Paediatric population Subcutaneous formulation The safety of pembrolizumab solution for injection for the trea
Eintrag öffnenKeytruda · 4.8 · Subcutaneous formulation The safety profile of KEYTRUDA solution for injection in combination with platinum do
Eintrag öffnenKoselugo · 4.8 · In addition, the safety of selumetinib for the granule formulation was evaluated in 36 paediatric patients (do
Eintrag öffnenKoselugo · 4.8 · In addition, the safety of selumetinib for the granule formulation was evaluated in 36 paediatric patients (do
Eintrag öffnenLatuda · 4.5 · Coadministration of lurasidone with diltiazem (slow-release formulation), a moderate CYP3A4 inhibitor, resulte
Eintrag öffnenLumigan · 4.5 · In clinical studies, LUMIGAN 0.3 mg/mL (multi-dose formulation) was used concomitantly with a number of differ
Eintrag öffnenLumigan · 4.8 · 24 Table 3 Additional adverse reactions seen with LUMIGAN 0.3 mg/ml (multi-dose formulation)
Eintrag öffnenLumigan · 4.8 · In clinical studies, over 1 800 patients have been treated with LUMIGAN 0.3 mg/ml (multi-dose formulation). On
Eintrag öffnen